Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019.
Where this comes from
- Record sourced from PubMed, PMID 32692379.
- Also identified by DOI 10.1001/jama.2020.6611 and PMC identifier PMC5362654.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study uses publicly available FDA.gov data to characterize trends in the US Food and Drug Administration’s use of Risk Evaluation and Mitigation Strategy (REMS) programs between 2008 and 2019 and to describe the number and classes of medications included, the strategies deployed, and the risks the program was intended to mitigate.